Patients who received later-line EGFR-TKI therapy for L858R-mutation-positive NSCLC characterized by BIM deletion polymorphism had a significant shorter PFS than did patient with wild-type BIM tumors (3.2 vs. 6.7 months, P=0.04). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.